Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,932 recruiting studies in this area right now.
By phase
- Not applicable2,031
- Phase 21,075
- Phase 1791
- Phase 1/Phase 2481
- Phase 3345
- Phase 4125
- Phase 2/Phase 384
Top conditions
- Multiple Myeloma328
- Acute Myeloid Leukemia279
- Lymphoma179
- Sickle Cell Disease134
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia96
- Follicular Lymphoma70
- Hematologic Malignancy67
- Hodgkin Lymphoma64
- Myelodysplastic Syndrome64
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm54
- Lymphedema49
- Acute Myeloid Leukemia (AML)48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center62
- City of Hope Medical Center58
- Mayo Clinic56
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital45
- Peking University People's Hospital43
Where studies are running
- California397
- Texas185
- Alabama157
- Maryland152
- Arizona127
- Massachusetts105
- Florida104
- New York96
- Ohio72
- Minnesota69
Recruiting studies4,932 total
- NCT05588154Recruiting
Donate blood and other samples to study blood cancers
This study asks healthy adults to provide blood, bone marrow (if needed), skin, saliva, and stool samples. Scientists use these samples to compare patterns related to myeloid (bone-marrow) blood cancers, which may help future research and tests.
Bethesda, MarylandAges 18–120 - NCT05554393RecruitingPhase 2
Treating intermediate-risk AML in younger adults
This trial compares three different drug combinations for younger adults (18-59) with intermediate-risk AML. You will be assigned to one of three groups: standard chemotherapy (cytarabine + daunorubicin), that same chemotherapy plus venetoclax, or venetoclax combined with azacitidine.
Birmingham, AlabamaAges 18–59 - NCT05581030RecruitingPhase 1
Newly diagnosed ALL: testing a treatment after Hyper-CVAD
This Phase 1 study looks at a treatment approach for people newly diagnosed with Philadelphia-negative B- or T-cell acute lymphoblastic leukemia (ALL) after completing a specific chemotherapy course called Hyper-CVAD 1A. It aims to see if the treatment can be given safely and how well it may work for this type of leukemia.
Tampa, FloridaAges 18–50 - NCT05592015RecruitingPhase 2
Ruxolitinib for T-cell large granular leukemia
This Phase 2 study tests ruxolitinib, a targeted medicine, to improve outcomes in T-cell large granular lymphocytic leukemia (T-LGLL). It is for people whose disease is causing symptoms or who have already tried other treatment, with specific blood, infection, and medication requirements.
Boston, MassachusettsAges 18 years+ - NCT05558319RecruitingPhase 3
New myeloma study comparing three treatment plans before transplant
This Phase 3 trial tests the best combination of medicines for newly diagnosed multiple myeloma patients who are headed to an autologous stem cell transplant (ASCT). It compares extended VRD plus versus Isa-VRD versus Isa-V-Iberdomide to see which approach works best and is tolerable.
Alcalá de Henares, MadridAges 18–65 - NCT05583721RecruitingPhase 2
PET scan study of heart filling and blood flow in sickle cell
This study uses a PET scan to look for links between abnormal heart “filling” problems and how well blood reaches the heart muscle in people with sickle cell disease. The results may help explain early heart changes in sickle cell and guide future care.
Memphis, TennesseeAges 18–21 - NCT05578326RecruitingPhase 2
Trilaciclib plus lurbinectidin for certain previously treated cancers
This Phase 2 study tests the combination of trilaciclib and lurbinectidin in adults whose cancer has already been treated, including with certain standard medicines. It aims to see if this combination can shrink tumors or slow cancer growth.
Lebanon, New HampshireAges 18 years+ - NCT05580601RecruitingPhase 1/Phase 2
Immunotherapy trial for children with relapsed or stubborn AML
This Phase 1/2 trial tests a lab-made immune-cell treatment (NK cells) for children with acute myeloid leukemia (AML) that has come back or did not respond to treatment. It aims to help the immune system attack leukemia cells in the bone marrow, especially when standard treatments have not worked.
Cincinnati, OhioAges 2 years+ - NCT05579678Recruiting
Personal rehab program after donor bone marrow transplant
This study looks at a personalized rehabilitation program for people who are eligible to receive a bone marrow transplant from a donor. The goal is to improve recovery and function after transplant.
Edmonton, AlbertaAges 18–70 - NCT05549661RecruitingPhase 1
Onvansertib for hard-to-treat CMML and MDS/MPN
This Phase 1 study tests onvansertib to see if it can help people with repeat or treatment-resistant chronic myelomonocytic leukemia (CMML) and MDS/MPN overlap. It also studies side effects and gathers blood/bone marrow samples to better understand how the treatment works.
Rochester, MinnesotaAges 18 years+ - NCT05558124RecruitingPhase 1
Tested CPX-351 with gemtuzumab for newly diagnosed AML
This Phase 1 trial tests a new combination of CPX-351 plus gemtuzumab ozogamicin for people newly diagnosed with acute myeloid leukemia (AML). It aims to find a safe dose and see how well the treatment works, especially when the leukemia cells carry a target called CD33.
Tampa, FloridaAges 18–70 - NCT05554939RecruitingPhase 1/Phase 2
CAR-T cells targeting CD19 for relapsed B-cell lymphoma
This Phase 1/2 trial studies an “off-the-shelf” (allogeneic) immune-cell therapy that targets CD19, a marker on many B-cell lymphomas. It’s for adults whose lymphoma has come back or didn’t respond to prior treatment, aiming to shrink tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18–75 - NCT05588284Enrolling by invitation
Check whether a special treatment protects vein valves after clot
This study enrolls people with an acute blood clot in the thigh or pelvis veins to see how well a procedure called PCDT (using a Zelante device) preserves the function of vein valves. It may help reduce complications like ongoing vein problems after a clot.
Chuzhou, AnhuiAges 18–80 - NCT05584631RecruitingPhase 1
Switching IVIG to weekly SCIG for CIDP treatment
This Phase 1 study compares IVIG given through an IV versus SCIG given under the skin, for people with CIDP. It aims to find the right weekly SCIG dose based on your current IVIG dose, which could make treatment more convenient.
New Brunswick, New JerseyAges 18–65 - NCT05567133Recruiting
Study markers that predict how sarcoidosis changes over time
This study follows adults with sarcoidosis to see which body “risk signals” (biomarkers) can predict whether the disease will get better or worse. It may help doctors monitor sarcoidosis more closely and choose the right treatment sooner.
Baltimore, MarylandAges 19 years+ - NCT05552222RecruitingPhase 3
New treatment combo study for newly diagnosed multiple myeloma
This phase 3 trial tests two different drug combinations to treat newly diagnosed multiple myeloma. It may help by aiming to control the cancer without using high-dose chemotherapy and stem cell transplant for people who can’t receive that approach.
Gilbert, ArizonaAges 18 years+ - NCT05579132RecruitingPhase 1/Phase 2
Study drug for relapsed or hard-to-treat B-cell leukemia
This early study tests MK-1045 in people with precursor B-cell acute lymphoblastic leukemia (B-ALL) that has come back or did not respond to earlier treatment. It may help shrink leukemia and improve remission in patients with limited options.
Chongqing, Chongqing MunicipalityAges 2 years+ - NCT05583617RecruitingPhase 1/Phase 2
Testing multiple treatments for multiple myeloma after prior therapy
This early-phase study tests how safe and effective several treatment approaches are for people with multiple myeloma who have already had other treatments. Depending on your myeloma features and prior care, a study drug combination may be offered to try to control the disease.
Randwick, New South WalesAges 18 years+ - NCT05586074RecruitingPhase 3
Test drug HEC73543 against chemo for FLT3-mutated AML
This Phase 3 study compares HEC73543 versus standard “salvage” chemotherapy in adults with AML that has come back or did not respond after first treatment. It’s designed for people whose leukemia has an FLT3-ITD mutation and may help improve response and outcomes.
HanzhouAges 18 years+ - NCT05568719RecruitingPhase 3
Testing gene therapy for hemophilia A or B
This Phase 3 trial is checking how safe and effective two gene therapies are for people with hemophilia A or hemophilia B. It only includes people who already received the study medicines through specific Pfizer studies, so it’s mainly for that existing participant group.
Rancho Cordova, CaliforniaAges 18 years+ - NCT05557695Recruiting
Acalabrutinib patient study for early access CLL in the UK
This observational study follows adults in the UK who started acalabrutinib through an early access program for chronic lymphocytic leukemia (CLL). It aims to learn what happens in real-world care after starting the medicine.
AylesburyAges 18–130 - NCT05587049Recruiting
Testing an oral medicine plus azacitidine to improve AML disease
This study looks at how a standard AML treatment plan affects a person’s disease status over time. It focuses on newly diagnosed adults who cannot safely get intensive chemotherapy, using oral venetoclax plus azacitidine.
Medellín, AntioquiaAges 18 years+ - NCT05582993RecruitingPhase 3
Study of rVWF for severe bleeding disorder in children
This Phase 3 trial tests vonicog alfa (an rVWF treatment) to prevent and control bleeding in children with severe von Willebrand disease (vWD). You may be able to join if your child has severe vWD and has been on prior clotting factor treatment with ongoing bleeding despite that care.
Birmingham, AlabamaAges Up to 17 years - NCT04166526Recruiting
Brain and brain-vessel MRI study in kids with sickle cell
This study uses MRI scans to understand how the brain and blood vessels are affected in children with sickle cell disease, including before and after certain treatments. It also includes healthy children for comparison and may help improve future monitoring and care.
Boston, MassachusettsAges 8–18
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,932 recruiting hematology studies from the U.S. registry right now, out of 7,407 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.